Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062

Mary E. R. O'Brien; Krzystof Konopa; Paul Lorigan; Lionel Bosquee; Ernest Marshall; Frederique Bustin; Sabine Margerit; Christian Fink; Jos A. Stigt; Anne Marie C. Dingemans; Baktiar Hasan; Jan Van Meerbeeck; Paul Baas

doi:10.1016/j.ejca.2011.05.020

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062

Mary E. R. O'Brien, Krzystof Konopa, Paul Lorigan, Lionel Bosquee, Ernest Marshall, Frederique Bustin, Sabine Margerit, Christian Fink, Jos A. Stigt, Anne Marie C. Dingemans, Baktiar Hasan, Jan Van Meerbeeck, Paul Baas

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2322-2330
Journal	European Journal of Cancer
Volume	47
Issue number	15
DOIs	https://doi.org/10.1016/j.ejca.2011.05.020
Publication status	Published - Oct 2011

Keywords

Small cell lung cancer
Amrubicin
Survival
Toxicity

Access to Document

10.1016/j.ejca.2011.05.020

Cite this

O'Brien, M. E. R., Konopa, K., Lorigan, P., Bosquee, L., Marshall, E., Bustin, F., Margerit, S., Fink, C., Stigt, J. A., Dingemans, A. M. C., Hasan, B., Van Meerbeeck, J., & Baas, P. (2011). Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. European Journal of Cancer, 47(15), 2322-2330. https://doi.org/10.1016/j.ejca.2011.05.020

O'Brien, Mary E. R. ; Konopa, Krzystof ; Lorigan, Paul ; Bosquee, Lionel ; Marshall, Ernest ; Bustin, Frederique ; Margerit, Sabine ; Fink, Christian ; Stigt, Jos A. ; Dingemans, Anne Marie C. ; Hasan, Baktiar ; Van Meerbeeck, Jan ; Baas, Paul. / Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. In: European Journal of Cancer. 2011 ; Vol. 47, No. 15. pp. 2322-2330.

@article{c1107e40ee7548a194583d3eae043791,

title = "Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062",

keywords = "Small cell lung cancer, Amrubicin, Survival, Toxicity",

author = "O'Brien, {Mary E. R.} and Krzystof Konopa and Paul Lorigan and Lionel Bosquee and Ernest Marshall and Frederique Bustin and Sabine Margerit and Christian Fink and Stigt, {Jos A.} and Dingemans, {Anne Marie C.} and Baktiar Hasan and {Van Meerbeeck}, Jan and Paul Baas",

year = "2011",

month = oct,

doi = "10.1016/j.ejca.2011.05.020",

language = "English",

volume = "47",

pages = "2322--2330",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "15",

}

O'Brien, MER, Konopa, K, Lorigan, P, Bosquee, L, Marshall, E, Bustin, F, Margerit, S, Fink, C, Stigt, JA, Dingemans, AMC, Hasan, B, Van Meerbeeck, J & Baas, P 2011, 'Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062', European Journal of Cancer, vol. 47, no. 15, pp. 2322-2330. https://doi.org/10.1016/j.ejca.2011.05.020

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. / O'Brien, Mary E. R.; Konopa, Krzystof; Lorigan, Paul; Bosquee, Lionel; Marshall, Ernest; Bustin, Frederique; Margerit, Sabine; Fink, Christian; Stigt, Jos A.; Dingemans, Anne Marie C.; Hasan, Baktiar; Van Meerbeeck, Jan; Baas, Paul.

In: European Journal of Cancer, Vol. 47, No. 15, 10.2011, p. 2322-2330.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062

AU - O'Brien, Mary E. R.

AU - Konopa, Krzystof

AU - Lorigan, Paul

AU - Bosquee, Lionel

AU - Marshall, Ernest

AU - Bustin, Frederique

AU - Margerit, Sabine

AU - Fink, Christian

AU - Stigt, Jos A.

AU - Dingemans, Anne Marie C.

AU - Hasan, Baktiar

AU - Van Meerbeeck, Jan

AU - Baas, Paul

PY - 2011/10

Y1 - 2011/10

KW - Small cell lung cancer

KW - Amrubicin

KW - Survival

KW - Toxicity

U2 - 10.1016/j.ejca.2011.05.020

DO - 10.1016/j.ejca.2011.05.020

M3 - Article

C2 - 21684151

VL - 47

SP - 2322

EP - 2330

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 15

ER -

O'Brien MER, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. European Journal of Cancer. 2011 Oct;47(15):2322-2330. https://doi.org/10.1016/j.ejca.2011.05.020